These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 22790483)
1. Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status. Ohno M; Narita Y; Miyakita Y; Okita Y; Matsushita Y; Yoshida A; Fukushima S; Ichimura K; Kayama T; Shibui S Brain Tumor Pathol; 2012 Oct; 29(4):183-91. PubMed ID: 22790483 [TBL] [Abstract][Full Text] [Related]
2. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting. Jain S; Gupta P; Shankar KB; Singh R; Siraj F J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575 [TBL] [Abstract][Full Text] [Related]
3. Molecular profile of tumors with oligodendroglial morphology: Clinical relevance. Geevar T; Pai R; Chacko G; Malepathi K; Patel B; John J; Chacko AG; Balakrishnan R; John S Neurol India; 2018; 66(6):1726-1731. PubMed ID: 30504574 [TBL] [Abstract][Full Text] [Related]
4. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844 [TBL] [Abstract][Full Text] [Related]
5. Analysis of the IDH1 codon 132 mutation in brain tumors. Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363 [TBL] [Abstract][Full Text] [Related]
6. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337 [TBL] [Abstract][Full Text] [Related]
7. IDH1 and IDH2 mutations in gliomas. Yan H; Parsons DW; Jin G; McLendon R; Rasheed BA; Yuan W; Kos I; Batinic-Haberle I; Jones S; Riggins GJ; Friedman H; Friedman A; Reardon D; Herndon J; Kinzler KW; Velculescu VE; Vogelstein B; Bigner DD N Engl J Med; 2009 Feb; 360(8):765-73. PubMed ID: 19228619 [TBL] [Abstract][Full Text] [Related]
8. Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma. Zhou YX; Wang JX; Feng M; Sun CM; Sun T; Chen GL; Du ZW J Mol Neurosci; 2012 Jul; 47(3):442-7. PubMed ID: 22113362 [TBL] [Abstract][Full Text] [Related]
9. [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas]. Liu QQ; Yin XX; Zou Y; Yu TP; Gong J; Chen XQ; Nie L; Xu M; Zhang MN; Zhou Q; Chen N Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):658-663. PubMed ID: 30220117 [No Abstract] [Full Text] [Related]
10. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas. Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898 [TBL] [Abstract][Full Text] [Related]
12. [Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma]. Pan Y; Qi XL; Wang LM; Dong RF; Zhang M; Zheng DF; Chang Q; Zhong YF Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):292-8. PubMed ID: 24004584 [TBL] [Abstract][Full Text] [Related]
13. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834 [TBL] [Abstract][Full Text] [Related]
14. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Ichimura K; Pearson DM; Kocialkowski S; Bäcklund LM; Chan R; Jones DT; Collins VP Neuro Oncol; 2009 Aug; 11(4):341-7. PubMed ID: 19435942 [TBL] [Abstract][Full Text] [Related]
15. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance. Thota B; Shukla SK; Srividya MR; Shwetha SD; Arivazhagan A; Thennarasu K; Chickabasaviah YT; Hegde AS; Chandramouli BA; Somasundaram K; Santosh V Am J Clin Pathol; 2012 Aug; 138(2):177-84. PubMed ID: 22904127 [TBL] [Abstract][Full Text] [Related]
16. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing. Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617 [TBL] [Abstract][Full Text] [Related]
17. IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy. Iwadate Y; Matsutani T; Hirono S; Ikegami S; Shinozaki N; Saeki N J Neurooncol; 2015 Sep; 124(3):493-500. PubMed ID: 26243269 [TBL] [Abstract][Full Text] [Related]
18. Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival. Yao Y; Chan AK; Qin ZY; Chen LC; Zhang X; Pang JC; Li HM; Wang Y; Mao Y; Ng HK; Zhou LF PLoS One; 2013; 8(6):e67421. PubMed ID: 23840696 [TBL] [Abstract][Full Text] [Related]
19. IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients. Chen N; Yu T; Gong J; Nie L; Chen X; Zhang M; Xu M; Tan J; Su Z; Zhong J; Zhou Q Pathology; 2016 Dec; 48(7):675-683. PubMed ID: 27780605 [TBL] [Abstract][Full Text] [Related]
20. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas. Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]